QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   431.10 (+0.01%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
Free Trial
NASDAQ:SLXP

Salix Pharmaceuticals (SLXP) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)
Free SLXP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
4.96 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
SLXP stock logo

About Salix Pharmaceuticals Stock (NASDAQ:SLXP)

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

SLXP Stock News Headlines

May 17, 2023 | benzinga.com
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029
April 6, 2023 | bizjournals.com
Pharmaceuticals News
April 16, 2024 | Manward Press (Ad)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
February 19, 2023 | thestreet.com
Why Salix Pharmaceuticals (SLXP) Stock Is Gaining Today
January 7, 2023 | thestreet.com
Salix Pharmaceuticals (SLXP) Stock Closed Lower Today as Valeant Looks to Increase Bid
December 31, 2022 | thestreet.com
Why Salix Pharmaceuticals (SLXP) Stock Is Soaring Today
December 25, 2022 | thestreet.com
Why Salix Pharmaceuticals (SLXP) Stock Is Surging Today
December 23, 2022 | thestreet.com
Valeant Pharmaceuticals (VRX) Stock Surges Today as Analyst Ups Price Target on Salix Deal
April 16, 2024 | Manward Press (Ad)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
September 9, 2022 | marketwatch.com
Bausch Health Says FDA Won't Fully Approve Generic Xifaxan Until 2029
September 4, 2022 | thestreet.com
Salix Acquisition Likely, but at What Price Is Open to Debate
July 28, 2022 | seekingalpha.com
Bausch Health plummets 50% following judge's Xifaxan patent order
July 18, 2022 | thestreet.com
DNDNQ News
June 20, 2022 | markets.businessinsider.com
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022
June 1, 2022 | thestreet.com
Jim Cramer's 'Mad Money' Recap: Calm Down, There's No Nasdaq Bubble
January 6, 2022 | thestreet.com
Stock Market Today: Futures Jump as Jobs Rebound in September
August 2, 2021 | finance.yahoo.com
Canada's Valeant to buy Salix in $10.1 billion deal
See More Headlines
Receive SLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Salix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SLXP
CUSIP
79543510
CIK
1009356
Web
www.salix.com
Phone
+1-919-8621000
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

SLXP Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Salix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salix Pharmaceuticals investors own include Allergan (AGN), Baidu (BIDU), Gilead Sciences (GILD), (QIHU) (QIHU), Capri (CPRI), 3D Systems (DDD), Intercept Pharmaceuticals (ICPT), Johnson & Johnson (JNJ) and

This page (NASDAQ:SLXP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
1970’s computer coder issues shocking A.I. warning
TradeSmith
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
How to Know Which AI Company to Invest In… and When
Banyan Hill Publishing